Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
Publication in refereed journal

香港中文大學研究人員

引用次數
替代計量分析
.

其它資訊
摘要The largest burden of hepatocellular carcinoma (HCC) lies in Asia, secondary to hepatitis B virus (HBV) infection. Improved survival with sorafenib has fostered new research but many challenges remain in designing clinical trials. The disease, its management, and populations affected by it are heterogeneous worldwide and within Asia. An expert conference of Eastern Asian oncologists and hepatologists was convened to foster consensus in clinical trial design. The panel identified key areas that need to be addressed to facilitate clinical trials in Asia. Stratification by viral etiology is desirable within Asia and by region in global trials. Antiviral therapy should also be considered as a stratification factor and incorporated into HCC management in trials. The panel agreed that histological diagnosis is not required for trial entry and that Barcelona-Clinic Liver Cancer (BCLC) staging is acceptable for trials as long as portal hypertension can be better defined with standardized methodology. Consensus in treatment must be sought to allow multi-national trials and it must be recognized that first-line sorafenib is not largely feasible in Asia. Finally, Asian nations must be urged to participate in clinical trials, many of which are ongoing, to advance new treatment options in this challenging disease.
著者Yeo W, Chen PJ, Furuse J, Han KH, Hsu C, Lim HY, Moon H, Qin SK, Yeoh EM, Ye SL
期刊名稱BMC Cancer
出版年份2010
月份11
日期10
卷號10
出版社BIOMED CENTRAL LTD
國際標準期刊號1471-2407
語言英式英語
Web of Science 學科類別Oncology; ONCOLOGY

上次更新時間 2020-24-10 於 00:45